Abstract
Purpose
Breast cancer is the most common malignancy in women worldwide. Although important therapeutic progress was achieved over the past decade, this disease remains a public health problem. In light of precision medicine, the identification of new prognostic biomarkers in breast cancer is urgently needed to stratify populations of patients with poor clinical outcome who may benefit from new personalized therapies. The microtubule cytoskeleton plays a pivotal role in essential cellular functions and is an interesting target for cancer therapy. Microtubule assembly and dynamics are regulated by a wide range of microtubule-associated proteins (MAPs), some of which have oncogenic or tumor suppressor effects in breast cancer.
Results
This review covers current knowledge on microtubule-associated tumor suppressors (MATS) in breast cancer and their potential value as prognostic biomarkers. We present recent studies showing that combinatorial expression of ATIP3 and EB1, two microtubule-associated biomarkers with tumor suppressor and oncogenic effects, respectively, improves breast cancer prognosis compared to each biomarker alone.
Conclusions
These findings are discussed regarding the increasing complexity of protein networks composed of MAPs that coordinate microtubule dynamics and functions. Further studies are warranted to evaluate the prognostic value of combined expression of different MATS and their interacting partners in breast cancer.
Similar content being viewed by others
References
Harbeck N, Gnant M (2017) Breast cancer. Lancet 389:1134–1150
Falco M, Palma G, Rea D, De Biase D, Scala S, D’Aiuto M et al (2016) Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol. https://doi.org/10.1098/rsob.160254
André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V et al (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:267–274
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N et al (2019) Genomic characterization of metastatic breast cancers. Nature 569:560–564
Low SK, Zembutsu H, Nakamura Y (2018) Breast cancer: the translation of big genomic data to cancer precision medicine. Cancer Sci 109:497–506
Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F (2017) Precision medicine in breast cancer: reality or utopia? J Transl Med 15:139
Akhmanova A, Steinmetz MO (2015) Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol 16:711–726
Jiang K, Toedt G, Montenegro Gouveia S, Davey NE, Hua S, van der Vaart B et al (2012) A proteome-wide screen for mammalian SxIP motif-containing microtubule plus-end tracking proteins. Curr Biol 22:1800–1807
Martin M, Akhmanova A (2018) Coming into focus: mechanisms of microtubule minus-end organization. Trends Cell Biol 28:574–588
Sung M, Giannakakou P (2014) BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 33:1418–1428
Hsu LC, White RL (1998) BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 95:12983–12988
Lotti LV, Ottini L, D’Amico C, Gradini R, Cama A, Belleudi F et al (2002) Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35:193–203
Louie RK, Bahmanyar S, Siemers KA, Votin V, Chang P, Stearns T et al (2004) Adenomatous polyposis coli and EB1 localize in close proximity of the mother centriole and EB1 is a functional component of centrosomes. J Cell Sci 117(Pt 7):1117–1128
Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H et al (2009) 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS ONE 4(10):e7239
Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP (2003) Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22:8125–8136
Rong R, Jin W, Zhang J, Sheikh MS, Huang Y (2004) Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 23:8216–8230
Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P et al (2009) VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11:994–1001
Morrison EE (2009) The APC-EB1 interaction. Adv Exp Med Biol 656:41–50
Honnappa S, Gouveia SM, Weisbrich A, Damberger FF, Bhavesh NS, Jawhari H et al (2009) An EB1-binding motif acts as a microtubule tip localization signal. Cell 138:366–376
Slep KC, Rogers SL, Elliott SL, Ohkura H, Kolodziej PA, Vale RD (2005) Structural determinants for EB1-mediated recruitment of APC and spectraplakins to the microtubule plus end. J Cell Biol 168:587–598
Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S et al (2015) Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Mol Med 7:299–314
Gao J, Huo L, Sun X, Liu M, Li D, Dong JT et al (2008) The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283:8802–8809
Munemitsu S, Souza B, Müller O, Albert I, Rubinfeld B, Polakis P (1994) The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 54:3676–3681
Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ (2007) The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 104:8869–8874
Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F et al (2001) FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 98:10374–10379
Muranen T, Grönholm M, Lampin A, Lallemand D, Zhao F, Giovannini M et al (2007) The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet 16:1742–1751
Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC (2013) ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res 73:2905–2915
Smole Z, Thoma CR, Applegate KT, Duda M, Gutbrodt KL, Danuser G et al (2014) Tumor suppressor NF2/Merlin is a microtubule stabilizer. Cancer Res 74:353–362
Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Ludueña RF, Barnes LD (1999) The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem 274:24378–24382
Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM (1999) Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 35:249–256
Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39:857–865
Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A et al (2014) Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 143:447–457
Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59:3866–3869
Lovat F, Ishii H, Schiappacassi M, Fassan M, Barbareschi M, Galligioni E et al (2014) LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Oncotarget 5:970–977
Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, Tucker JA et al (2011) Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem 286:40376–40385
Hagrass HA, Pasha HF, Shaheen MA, Abdel Bary EH, Kassem R (2014) Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep 41:57–65
Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG (2007) The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med 20:605–611
Hu D, Zhou Z, Davidson NE, Huang Y, Wan Y (2012) Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. J Biol Chem 287:13584–13597
Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT et al (2001) Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 7:1998–2004
Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T et al (2002) Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 8:2890–2893
Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F et al (2009) Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat 116:471–478
Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Physiol 196:19–41
Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J et al (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33:679–689
Song H, Li D, Wu T, Xie D, Hua K, Hu J et al (2018) MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep 51:602–607
Hou X, Niu Z, Liu L, Guo Q, Li H, Yang X et al (2019) miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol Lett 17:990–998
Huszno J, Kołosza Z, Grzybowska E (2019) BRCA1 mutation in breast cancer patients: analysis of prognostic factors and survival. Oncol Lett 17:1986–1995
Ginestier C, Bardou VJ, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J et al (2003) Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer 107:854–862
Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, Leal C et al (2011) High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 129:1–9
Di Benedetto M, Bièche I, Deshayes F, Vacher S, Nouet S, Collura V et al (2006) Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 380:127–136
Rodrigues-Ferreira S, Nahmias C (2010) An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab 21:684–690
Gupta GD, Coyaud É, Gonçalves J, Mojarad A, Liu Y, Wu Q et al (2015) Dynamic protein interaction landscape of the human centrosome–cilium interface. Cell 163:1484–1499
Velot L, Molina A, Rodrigues-Ferreira S, Nehlig A, Bouchet BP, Morel M et al (2015) Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3. Oncotarget 6:43557–43570
Nehlig A, Molina A, Rodrigues-Ferreira S, Honoré S, Nahmias C (2017) Regulation of end-binding protein EB1 in the control of microtubule dynamics. Cell Mol Life Sci 74:2381–2393
Dong X, Liu F, Sun L, Liu M, Li D, Su D et al (2010) Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol 220:361–369
Rodrigues-Ferreira S, Nehlig A, Monchecourt C, Nasr S, Fuhrmann L, Lacroix-Triki M et al (2019) Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis. Breast Cancer Res Treat 173:573–583
Almeida TB, Carnell AJ, Barsukov IL, Berry NG (2017) Targeting SxIP-EB1 interaction: an integrated approach to the discovery of small molecule modulators of dynamic binding sites. Sci Rep 7:15533
Wen Y, Eng CH, Schmoranzer J, Cabrera-Poch N, Morris EJ, Chen M et al (2004) EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. Nat Cell Biol 6:820–830
Green RA, Wollman R, Kaplan KB (2005) APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 16:4609–4622
Li D, Gao J, Yang Y, Sun L, Suo S, Luo Y et al (2014) CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration. Cell Cycle 13:974–983
Silva Soares EW, de Lima Santos SC, Bueno AG, Cavalli IJ, Cavalli LR, Fouto Matias JE et al (2010) Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer. Cancer Genet Cytogenet 199:24–30
Funding
This work has been funded by Gustave Roussy Cancer Center, the ANR Grant MMO ANR-10-IBHU-0001, the Comité Ile-de-France of the Ligue Nationale contre le Cancer, the Ligue contre le Cancer 94/Val-de-Marne, the Entreprises contre le cancer (GEFLUC) Ile-de-France, the Fondation ARC pour la recherche contre le cancer, the CNRS, the INSERM, the Fondation Janssen Horizon, the Fonds de Dotation Agnès b., the association Odyssea and Prolific.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rodrigues-Ferreira, S., Molina, A. & Nahmias, C. Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer. Breast Cancer Res Treat 179, 267–273 (2020). https://doi.org/10.1007/s10549-019-05463-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05463-x